Skip to main content
logo

Sopharma AD (BUL:SFA)

Bulgaria flag Bulgaria · Delayed Price · Currency is BGN · Price in EUR
2.070
+0.115 (5.88%)
At close: Aug 21, 2026
Market Cap2.13B +73.2%
Revenue (ttm)2.68B +20.1%
Net Income154.80M +81.5%
EPS0.44 +172.9%
Shares Out 528.43M
PE Ratio8.99
Forward PEn/a
Dividend0.06 (1.47%)
Ex-Dividend DateJul 9, 2026
Volume55,721
Open1.960
Previous Close1.955
Day's Range1.960 - 2.080
52-Week Range1.243 - 2.080
Beta0.08
Analystsn/a
Price Targetn/a
Earnings DateJul 30, 2026

About Sopharma AD

Sopharma AD produces, distributes, and exports pharmaceutical products in Europe, Bulgaria, and internationally. It offers Carsil to treat liver disease; Tempalgin, a painkiller; Analgin, a pain reliever; Tabex, a drug used for smoking secession; Tribestan, a drug used for stimulation of the male reproductive system; Broncholytin, which is used to suppress cough; Nivalin for use in the peripheral nervous system; Methylprednisolon for severe allergies and life-threatening conditions; Vitamin C; Valeriana, a herbal medicine to reduce the stress; ... [Read more]

Industry Pharmaceutical Preparations
Founded 1933
Employees 6,005
Stock Exchange Bulgarian Stock Exchange
Ticker Symbol SFA
Full Company Profile

Financial Performance

In 2025, Sopharma AD's revenue was 1.35 billion, an increase of 22.31% compared to the previous year's 1.10 billion. Earnings were 68.30 million, an increase of 74.61%.

Financial numbers in EUR Financial Statements